- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01013597
Trial of LBH589 in Metastatic Thyroid Cancer
A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer
Study Overview
Detailed Description
Medullary thyroid cancer (MTC) is a neuroendocrine tumor and accounts for 3-5% of cases of thyroid cancer. The majority of patients with MTC do not present with early stage disease. Differentiated thyroid cancer (DTC) accounts for >90% of all thyroid cancers. In a sub-set of patients, thyroid cells become resistant to I-131 radioiodine therapy and subsequently develop distant metastases. In both MTC and DTC, systemic chemotherapy for metastatic disease is largely ineffective.
LBH589 is a histone deacetylase (HDAC) with recently demonstrated activity to inhibit the Notch1 signaling pathway in MTC cancer cells and suppress tumor cell proliferation in DTC cancer cells. This clinical trial will evaluate the tumor response rate of LBH589 in patients with metastatic MTC or radioactive iodine resistant DTC.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54301
- St. Vincent Regional Cancer Center CCOP
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin - Madison
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed metastatic medullary or differentiated thyroid cancer. Diagnosis must be confirmed at University of Wisconsin
- Patients must have measurable disease as defined by RECIST.
- At least 3 weeks from the completion of major surgery, chemotherapy, or other systemic therapy or local liver therapy to study registration
- No concurrent chemotherapy or radiation therapy
- ECOG Performance Status of ≤ 2
- Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- Adequate bone marrow, kidney, liver function
- Left ventricular ejection fraction ≥ the lower limit of the institutional normal
- Those with differentiated thyroid cancer must have radioactive iodine resistant disease, defined by failure to incorporate 131-Iodine after therapy, FDG-avidity on a PET scan, or progression of measurable disease after 131-Iodine therapy or an allergy to radioactive iodine
- Hypertension must be well controlled (to less than 150/90 mmHg) on a stable regimen of anti-hypertensive therapy
Exclusion Criteria:
- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment
- Impaired cardiac function
- Concomitant use of drugs with a risk of causing torsades de pointes
- Patients with unresolved diarrhea > CTCAE grade 1
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589
- Other concurrent severe and/or uncontrolled medical conditions
- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after last study drug administration. Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589.
- Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment
- Patients with a history of another primary malignancy that, in the opinion of the investigator, would interfere with the assessment of the primary endpoints of the study
- Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C
- Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LBH589
|
LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response Rate to LBH589.
Time Frame: Every 8 weeks.
|
per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v.1.0)
for target lesions and assessed by CT/MRI: "Response" includes Complete Response (CR, disappearance of all target lesions), or Partial Response (PR, >=30% decrease in the sum of the longest diameter of target lesions).
"No Response" includes Stable Disease (SD, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease), and Progressive Disease (PD, at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s).)
|
Every 8 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Protein Expression Patterns of Notch1 in Thyroid Tissue Samples.
Time Frame: End of study
|
End of study
|
|
Time to Progression of Thyroid Cancer
Time Frame: Every 3 months until progression up to 5 years
|
Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time to progression is defined as the number of days from the day of first LBH589 administration to the day the patient experienced an event of disease progression or death, whichever came first.
Progression was assessed every 3 months until death or up to 5 years, whichever occurred first.
|
Every 3 months until progression up to 5 years
|
Overall Survival
Time Frame: Every 3 months up to 5 years
|
For a given patient, overall survival (OS) is defined as the number of days from the day of first LBH589 administration until the patient's death.
If a patient was alive at the time of analysis, then the patient's data is censored at the date of the last available evaluation.Survival was assessed every three months until death or final data analysis, whichever occurred first.
|
Every 3 months up to 5 years
|
Impact of LBH589 on Tumor Markers for Thyroid Cancer
Time Frame: Baseline and end of treatment, up to 1 year
|
Change in serum Thyroglobulin level from baseline to end of treatment.
Treatment continued until either extraordinary medical circumstances, disease progression, toxicity, subject withdrawal, or death.
At the time subjects came off of study treatment for one of the reasons already listed, a sample was collected for tumor markers.
|
Baseline and end of treatment, up to 1 year
|
Toxicity of LBH589
Time Frame: Every 4 weeks, up to 5 years
|
Most frequent toxicities at least possibly related to panobinostat, grades 2-4 (grading based on NCI common terminology criteria for adverse events CTCAE version 3).
Toxicities were collected from the time the patient provided informed consent until 4 weeks after the patient stopped LBH589.
|
Every 4 weeks, up to 5 years
|
Tolerability of LBH589
Time Frame: Every 4 weeks, up to 5 years
|
Tolerability and toxicity were not assessed separately, therefore tolerability is reported as toxicity.
|
Every 4 weeks, up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anne Traynor, M.D., University of Wisconsin, Madison
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-2009-0173 (Other Identifier: Institutional Review Board)
- A534260 (Other Identifier: UW Madison)
- SMPH\MEDICINE\HEM-ONC (Other Identifier: UW Madison)
- CO08322 (Other Identifier: University of Wisconsin Carbone Cancer Center)
- NCI-2011-00715 (Registry Identifier: NCI Trial ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Carcinoma
-
National Cancer Institute (NCI)ExelixisCompletedRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRefractory Differentiated Thyroid Gland Carcinoma | Unresectable Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell CarcinomaUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPoorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedPoorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...United States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Follicular Carcinoma | Stage IV Thyroid Gland Follicular CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Thyroid Gland Medullary Carcinoma | Thyroid Gland Papillary Carcinoma | Malignant Thyroid Gland NeoplasmUnited States
-
The First Affiliated Hospital of Xiamen UniversityRecruitingRefractory Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell CarcinomaChina
Clinical Trials on LBH589
-
Novartis PharmaceuticalsTerminatedLeukemia-Lymphoma, Adult T-Cell | Cutaneous T-Cell LymphomaJapan
-
Abdullah KutlarSecura Bio, Inc.RecruitingSickle Cell DiseaseUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...NovartisTerminatedBrain Metastasis | Recurrent Glioma | High-grade MeningiomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Anne Beaven, MDNovartisTerminatedDiffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER-2 Positive Breast CancerBelgium, Netherlands, Australia, Italy, United States
-
H. Lee Moffitt Cancer Center and Research InstituteNovartis PharmaceuticalsCompletedMultiple MyelomaUnited States
-
Novartis PharmaceuticalsCompletedLymphoma | Leukemia | Multiple MyelomaUnited States, Germany, Australia